Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck

Table 1 Overview of the results of overall survival and progression-free survival efficacy of immunotherapy based-consolidation studies (PACIFIC, LUN 14-179) and historic attempts to improve overall survival in stage III non-small cell lung cancer (PROCLAIM and RTOG 0617)

Endpoint	Study and treatment
	PACIFIC durvalumab	PACIFIC placebo	LUN 14-179 pembrolizumab	PROCLAIM pemetrexed	RTOG 0617 (60 Gy RT)	RTOG 0617 cetuximab
Median follow-up	33.3 mo	33.3 mo	18.6 mo	22.2 mo	22.9 mo	21.3 mo
OS
Median	NR	29.1 mo	22.4 mo	26.8 mo	28.7 mo	25 mo
12-mo	83.1%	74.6%	74.7%	76%	80%	76.2%
24-mo	66.3%	55.3%		52%	57.6%	52.3%
36-mo	57%	43.5%		40%
PFS
Median	17.2 mo	5.6 mo	17 mo	11.4 mo	11.8 mo	10.8 mo
12-mo	55.9%	35.3%	60.2%		49.2%	44.3%
24-mo			44.6%		29.1%	24.2%

OS: Overall survival; PFS: Progression-free survival; RT: Radiotherapy.